TABLE 3

Unadjusted and adjusted effects of ICU status on susceptibilitya

Effect and antibioticSingle agentFQ combinationAG combination
OR95% CIPOR95% CIPOR95% CIP
Unadjusted effects for non-ICU vs ICU status
    ESC1.121.02–1.220.01321.131.02–1.250.02410.880.78–0.990.0410
    Carb1.331.21–1.45<0.00011.301.18–1.44<0.00011.020.90–1.160.7211
    TZP1.201.08–1.330.00051.161.03–1.320.01620.950.82–1.100.5103
    AG0.810.73–0.89<0.00010.950.85–1.060.3415NANANA
    FQ1.050.96–1.140.2752NANANA0.950.85–1.060.3415
GLMM-adjusted effectsb for non-ICU vs ICU status
    ESC1.060.96–1.170.23201.050.94–1.180.39870.830.72–0.940.0048
    Carb1.271.15–1.40<0.00011.211.08–1.350.00090.960.84–1.090.5211
    TZP1.141.02–1.270.02171.070.94–1.230.30230.910.78–1.060.2324
    AG0.760.69–0.85<0.00010.890.79–1.010.0683NANANA
    FQ0.960.88–1.050.3954NANANA0.890.79–1.010.0683
  • a Numbers indicate the effect size of non-ICU status; i.e., an odds ratio of 1.12 for single-agent ESC indicates that the odds of a P. aeruginosa isolate being susceptible to ESC is 12% higher for non-ICU isolates than for ICU isolates. Abbreviations: AG, aminoglycoside (gentamicin, tobramycin, amikacin); Carb, carbapenem (imipenem, meropenem); CI, confidence interval; ESC, extended-spectrum cephalosporins (ceftazidime, cefepime); FQ, fluoroquinolone (ciprofloxacin, levofloxacin); GLMM, generalized linear mixed models; ICU, intensive care unit; NA, not applicable; OR, odds ratio; TZP, piperacillin-tazobactam.

  • b Effects were adjusted using GLMM. Adjusting variables include source (blood/respiratory), onset (admission/hospital), and hospital characteristics (teaching status, bed size, urban/rural, geographic region).